drugset / Trial / NCT02772562

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

NCT02772562

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see how well PROSTVAC -V/F works in stopping prostate cancer from coming back or relapsing. This study will also look at the safety of PROSTVAC-V/F.

Timeline

Start
2016-07-18
Primary completion
2024-04-29
Completion
2024-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject PROSTVAC-F Vaccine 1e+09 iu
Subject PROSTVAC-V Vaccine 2e+08 iu

Indications